Trachoma remains the world's leading infectious cause of blindness, a distinction made more painful by the fact that it is entirely preventable. This article explains how a single oral dose of azithromycin became the antibiotic pillar of the World Health Organization's four-part SAFE strategy, what the clinical trial evidence actually shows, and why drug treatment alone was never meant to carry the whole burden of elimination.

Trachoma: The World's Leading Infectious Cause of Blindness

Trachoma is caused by repeated conjunctival infection with Chlamydia trachomatis, serovars A through C. A single infection in childhood is unremarkable and often clears. The damage comes from repeated infections, year after year, in households and villages where the bacterium circulates freely on hands, cloth, and the flies that land on unwashed children's faces. Chronic inflammation gradually scars the inside of the eyelid. Over years, that scarring pulls the eyelashes inward, a condition called trichiasis, in which the lashes scrape the cornea with every blink. Left untreated, this produces corneal opacity and irreversible blindness, typically in adulthood, after decades of childhood exposure.

The disease clusters in poor, rural communities with limited access to clean water, largely across sub-Saharan Africa, parts of the Middle East, South Asia, and Latin America. Women are affected roughly twice as often as men, likely because of closer, more prolonged contact with infected children as primary caregivers. This is a disease of poverty and water scarcity as much as it is a disease of bacteria, and that fact shapes everything about how it is fought.

The SAFE Strategy: Four Pillars, One Goal

The World Health Organization has organized trachoma control around an acronym that deserves to be read in full, because each letter represents a genuine intervention rather than a slogan:

The order of the letters is not accidental. Surgery treats the already-damaged. Antibiotics suppress current infection. Facial cleanliness and environmental improvement address the reasons infection keeps recurring in the first place. A mass drug administration campaign that skips the F and E components is treating a symptom of poverty with a pill, and the World Health Organization has been explicit that antibiotics alone do not produce lasting elimination. This is a point worth sitting with: real, durable health in a community usually depends on infrastructure and habit as much as on medicine, and a family that has access to clean water and teaches its children to wash their faces is doing as much for its long-term health as any clinic visit.

From Weeks of Ointment to One Dose: The Azithromycin Trials

Before azithromycin, the standard antibiotic treatment for trachoma was topical tetracycline eye ointment, applied twice daily for six weeks. It worked biologically, but compliance in the field was poor; asking a rural household to apply ointment to a child's eyes twice a day for over a month, month after month, across an entire village, is a program administrator's nightmare.

The turning point came from a randomized controlled trial published in The Lancet in 1999 by Julius Schachter, Sheila West, David Mabey, and colleagues, conducted in Tanzania. The trial compared a single oral dose of azithromycin against six weeks of topical tetracycline and found clinical and microbiological cure rates that were essentially comparable, with markedly better adherence in the azithromycin arm because it required only one supervised dose rather than weeks of self-administered ointment. This single trial reshaped global trachoma policy: a drug that could be given once, under direct observation, at the moment a health worker was standing in front of a family, was operationally transformative in a way that a six-week regimen could never be, however similar the underlying pharmacology.

Later community-level studies, including work associated with the Partnership for Rapid Elimination of Trachoma (PRET) conducted by investigators from the University of California, San Francisco's Proctor Foundation across sites in Tanzania and elsewhere, examined how often mass treatment needed to be repeated and at what population coverage to meaningfully suppress ocular chlamydial infection. These studies, published through the 2010s, generally found that annual mass treatment at high coverage reduced infection prevalence substantially, though infection could return between rounds in the highest-burden communities, reinforcing that repeated rounds combined with hygiene and sanitation improvements, not a single campaign, were necessary for lasting control.

How Mass Drug Administration Works in the Field

WHO guidance ties the decision to treat an entire community to a specific epidemiological threshold: when the prevalence of active trachoma (trachomatous inflammation, follicular, or TF) among children aged 1 to 9 reaches 5 percent or higher in a district, mass drug administration is recommended for the whole population of that district, not just those with visible signs of infection. This is a deliberate design choice. Ocular chlamydial infection can be present and transmissible without obvious symptoms, particularly in young children, so treating only the visibly affected leaves a reservoir of infection that will simply reseed the community.

Dosing follows a weight-based single-dose regimen, roughly 20 mg/kg up to a maximum of 1 gram, given once by mouth. Children too young to safely receive the oral suspension, and a small number of individuals with contraindications, are typically offered topical tetracycline instead. It bears repeating that these are public-health program dosing guidelines set by WHO for community campaigns; azithromycin's approved uses and dosing for individual patients are determined by regulatory authorities and prescribing clinicians in each country, and anyone receiving the drug, in a campaign or a clinic, has the right to understand what they are being given and why, and to ask questions of the health worker or physician administering it.

The Global Trachoma Mapping Project, coordinated in the 2010s by the International Coalition for Trachoma Control and described in Ophthalmic Epidemiology by Anthony Solomon and colleagues, surveyed more than two million people across nearly thirty countries to identify exactly which districts met the treatment threshold. It remains one of the largest population-based surveys ever conducted for a single infectious disease and gave program planners, for the first time, a genuinely global and standardized map of where mass treatment was actually warranted, rather than relying on older, patchier estimates.

Antibiotic Stewardship: What the Evidence Says About Resistance

Any program that distributes an antibiotic to entire populations, repeatedly, raises a fair question: what does this do to antimicrobial resistance more broadly? The honest answer is that the evidence here is real but limited in scope, and it deserves to be stated plainly rather than glossed over.

Studies nested within mass azithromycin programs, including surveillance work following campaigns in Ethiopia and elsewhere, have documented increased carriage of macrolide-resistant Streptococcus pneumoniae and other nasopharyngeal organisms in treated communities following rounds of mass azithromycin distribution. This resistance has generally been shown to be transient, declining after treatment rounds stop, but it has not been shown to be zero-consequence, and researchers have continued to monitor it as programs expand.

A related and larger body of evidence comes from the MORDOR trial, a cluster-randomized study led by Jeremy Keenan and colleagues and published in the New England Journal of Medicine in 2018, which tested biannual azithromycin distribution to young children in Niger, Malawi, and Tanzania for child mortality reduction, a distinct but overlapping use of mass azithromycin distribution in some of the same populations. That trial found a meaningful reduction in all-cause childhood mortality, but its investigators and independent commentators also flagged the resistance question as an open one requiring ongoing surveillance, not a settled matter. Programs today generally try to limit mass distribution to the frequency and duration actually needed to reach elimination thresholds, precisely because indefinite mass antibiotic use is not treated as a cost-free tool. This is stewardship in the fullest sense: a powerful medicine, drawn originally from work on erythromycin-class compounds derived from soil-dwelling actinomycetes, is not something to be dispensed carelessly, because its usefulness for future generations depends on using it wisely now.

Measuring Success: Elimination as a Public Health Problem

WHO does not claim to eradicate the bacterium worldwide; the formal goal is elimination of trachoma "as a public health problem," a defined threshold requiring, among other criteria, TF prevalence below 5 percent in children and a very low backlog of untreated trichiasis cases, sustained for at least two years after mass treatment ends. As of the early 2020s, WHO had validated more than twenty countries as having reached this threshold, including Ghana, Nepal, Morocco, Mexico, and Iran, among others, each verified through independent population-based surveys rather than program self-reporting.

These successes share a common pattern: they combined mass azithromycin distribution with real investment in latrines, water access, and surgical outreach, sustained over years, not a single donated round of pills. That pattern is the honest lesson of the SAFE strategy. Medicine did its part well; azithromycin's single-dose regimen made mass treatment logistically possible in places where a six-week ointment course never would have worked. But the communities that actually crossed the finish line were the ones that also built latrines, dug wells, and taught children to wash their faces, decade after decade. That is not a story about a wonder drug. It is a story about a good drug used wisely, inside a broader and more patient commitment to caring for the vulnerable.

Key takeaway: Single-dose azithromycin made mass treatment for trachoma logistically feasible, but the disease is only truly eliminated where drug treatment is joined to surgery, hygiene, and lasting improvements in water and sanitation.